

Phospho-NR4A1-S351 Antibody Blocking Peptide Synthetic peptide Catalog # BP3288a

Specification

Phospho-NR4A1-S351 Antibody Blocking Peptide - Product Information

Other Accession

<u>Q9Z239</u>

Phospho-NR4A1-S351 Antibody Blocking Peptide - Additional Information

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP3288a was selected from the region of human Phospho-NR4A1-S351. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Phospho-NR4A1-S351 Antibody Blocking Peptide - Protein Information

Phospho-NR4A1-S351 Antibody Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

Phospho-NR4A1-S351 Antibody Blocking Peptide - Images

Phospho-NR4A1-S351 Antibody Blocking Peptide - Background

NR4A1 is a member of the steroid-thyroid hormone-retinoid receptor superfamily. Expression is induced by phytohemagglutinin in human lymphocytes and by serum stimulation of arrested fibroblasts. The encoded protein acts as a nuclear transcription factor. Translocation of the protein from the nucleus to mitochondria induces apoptosis.

Phospho-NR4A1-S351 Antibody Blocking Peptide - References

Lu, L., et al., J. Clin. Endocrinol. Metab. 89(8):4113-4118 (2004).Castro-Obregon, S., et al., J. Biol. Chem. 279(17):17543-17553 (2004).Lin, B., et al., Cell 116(4):527-540 (2004).Choi, J.W., et al.,



Cancer Res. 64(1):35-39 (2004).Ye, X., et al., Int. J. Biochem. Cell Biol. 36(1):98-113 (2004).